开云app官网登录入口网页版-官方正版

#贝伐珠#

101篇内容 | 2191人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1954870, encodeId=43a419548e008, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效, objectType=article, longId=301244, objectId=cf6f3012449f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf6f3012449f, replyNumber=0, likeNumber=92, createdTime=2022-12-13, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf6f3012449f, moduleTitle=Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cf6f3012449f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954866, encodeId=3b08195486629, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Transl Lung Cancer Res: 随机II期研究比较贝伐珠单抗联合不同铂类化疗方案治疗晚期非鳞状非小细胞肺癌(nsNSCLC)的疗效, objectType=article, longId=295291, objectId=de9929529101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de9929529101, replyNumber=0, likeNumber=87, createdTime=2022-05-21, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de9929529101, moduleTitle=Transl Lung Cancer Res: 随机II期研究比较贝伐珠单抗联合不同铂类化疗方案治疗晚期非鳞状非小细胞肺癌(nsNSCLC)的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=de9929529101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954865, encodeId=c4b61954865dd, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, objectType=article, longId=295378, objectId=2fbf2953e8d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fbf2953e8d9, replyNumber=0, likeNumber=84, createdTime=2022-09-30, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fbf2953e8d9, moduleTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2fbf2953e8d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954860, encodeId=67cb195486019, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Chin J Cancer Res：中肿徐瑞华教授团队IV期观察性研究：评估中国转移性结直肠癌使用化疗联合贝伐珠单抗治疗的真实世界疗效和安全性, objectType=article, longId=292555, objectId=6a7d292555c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a7d292555c6, replyNumber=0, likeNumber=84, createdTime=2022-03-24, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a7d292555c6, moduleTitle=Chin J Cancer Res：中肿徐瑞华教授团队IV期观察性研究：评估中国转移性结直肠癌使用化疗联合贝伐珠单抗治疗的真实世界疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6a7d292555c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954877, encodeId=087719548e7d0, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=肿瘤笔记：一文掌握关于贝伐珠单抗临床相关的70个细节问题, objectType=article, longId=730174, objectId=a09fe3017471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a09fe3017471, replyNumber=0, likeNumber=120, createdTime=2023-04-25, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a09fe3017471, moduleTitle=肿瘤笔记：一文掌握关于贝伐珠单抗临床相关的70个细节问题, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a09fe3017471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954843, encodeId=6d76195484313, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗对肺腺癌脑转移伴难治性脑水肿患者生活质量及血清 VEGF水平的影响, objectType=article, longId=220772, objectId=5716220e7251, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5716220e7251, replyNumber=0, likeNumber=77, createdTime=2022-02-20, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5716220e7251, moduleTitle=贝伐珠单抗对肺腺癌脑转移伴难治性脑水肿患者生活质量及血清 VEGF水平的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5716220e7251)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954847, encodeId=5507195484e77, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=放疗联合贝伐珠单抗治疗肺腺癌脑转移瘤伴脑水肿的临床效果, objectType=article, longId=220776, objectId=2c90220e7682, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c90220e7682, replyNumber=0, likeNumber=84, createdTime=2022-08-15, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c90220e7682, moduleTitle=放疗联合贝伐珠单抗治疗肺腺癌脑转移瘤伴脑水肿的临床效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2c90220e7682)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954869, encodeId=07da1954869c7, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当, objectType=article, longId=300931, objectId=f500300931ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f500300931ea, replyNumber=0, likeNumber=108, createdTime=2022-08-30, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f500300931ea, moduleTitle=Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f500300931ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954878, encodeId=010619548e84a, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=建议收藏！贝伐珠单抗的4大常见不良反应，如何处理？, objectType=article, longId=732446, objectId=6cfee32446f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cfee32446f8, replyNumber=0, likeNumber=95, createdTime=2023-01-08, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cfee32446f8, moduleTitle=建议收藏！贝伐珠单抗的4大常见不良反应，如何处理？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6cfee32446f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954871, encodeId=b22419548e15b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=关于贝伐珠单抗，你想知道的全在这里, objectType=article, longId=726226, objectId=ce72e262261f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce72e262261f, replyNumber=0, likeNumber=121, createdTime=2022-07-26, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce72e262261f, moduleTitle=关于贝伐珠单抗，你想知道的全在这里, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ce72e262261f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954876, encodeId=4c8019548e626, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗的中国人群标准剂量是多少？你真的知道吗？, objectType=article, longId=729270, objectId=e19ae2927019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e19ae2927019, replyNumber=0, likeNumber=91, createdTime=2022-09-06, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e19ae2927019, moduleTitle=贝伐珠单抗的中国人群标准剂量是多少？你真的知道吗？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e19ae2927019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954855, encodeId=37951954855b6, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, objectType=article, longId=221101, objectId=e69e221101af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e69e221101af, replyNumber=0, likeNumber=95, createdTime=2022-02-01, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e69e221101af, moduleTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e69e221101af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954875, encodeId=2c2e19548e545, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, objectType=article, longId=728863, objectId=e46de28863d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46de28863d9, replyNumber=0, likeNumber=96, createdTime=2022-10-30, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46de28863d9, moduleTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e46de28863d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954844, encodeId=d7541954844c2, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗治疗非小细胞肺癌脑转移瘤放射治疗后难治性瘤周水肿疗效观察, objectType=article, longId=220773, objectId=9a41220e7350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a41220e7350, replyNumber=0, likeNumber=83, createdTime=2022-01-17, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a41220e7350, moduleTitle=贝伐珠单抗治疗非小细胞肺癌脑转移瘤放射治疗后难治性瘤周水肿疗效观察, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9a41220e7350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954872, encodeId=0d7919548e295, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗和安罗替尼在使用时如何选择？, objectType=article, longId=727344, objectId=2fede273441e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fede273441e, replyNumber=0, likeNumber=77, createdTime=2022-11-21, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fede273441e, moduleTitle=贝伐珠单抗和安罗替尼在使用时如何选择？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2fede273441e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954874, encodeId=b70119548e4ea, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效, objectType=article, longId=727599, objectId=801de275994a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=801de275994a, replyNumber=0, likeNumber=86, createdTime=2022-08-31, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=801de275994a, moduleTitle=J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=801de275994a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954864, encodeId=db59195486451, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, objectType=article, longId=295174, objectId=ce4f2951e4a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4f2951e4a6, replyNumber=0, likeNumber=86, createdTime=2022-08-31, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4f2951e4a6, moduleTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ce4f2951e4a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954863, encodeId=007919548638c, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, objectType=article, longId=294716, objectId=db94294e16ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db94294e16ed, replyNumber=0, likeNumber=79, createdTime=2022-08-28, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db94294e16ed, moduleTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=db94294e16ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954862, encodeId=f2121954862a0, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后, objectType=article, longId=293790, objectId=a320293e9099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a320293e9099, replyNumber=0, likeNumber=80, createdTime=2022-05-10, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a320293e9099, moduleTitle=Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a320293e9099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954852, encodeId=26401954852f1, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗的加入让宫颈癌治疗不再“谈虎色变”（妇科肿瘤）, objectType=article, longId=220796, objectId=e513220e9674, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e513220e9674, replyNumber=0, likeNumber=60, createdTime=2022-08-02, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e513220e9674, moduleTitle=贝伐珠单抗的加入让宫颈癌治疗不再“谈虎色变”（妇科肿瘤）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e513220e9674)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

贝伐珠

2020-05-29

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效

2022-12-13

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Transl Lung Cancer Res: 随机II期研究比较贝伐珠单抗联合不同铂类化疗方案治疗晚期非鳞状非小细胞肺癌(nsNSCLC)的疗效

2022-05-21

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后

2022-09-30

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Chin J Cancer Res：中肿徐瑞华教授团队IV期观察性研究：评估中国转移性结直肠癌使用化疗联合贝伐珠单抗治疗的真实世界疗效和安全性

2022-03-24

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

肿瘤笔记：一文掌握关于贝伐珠单抗临床相关的70个细节问题

2023-04-25

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗对肺腺癌脑转移伴难治性脑水肿患者生活质量及血清 VEGF水平的影响

2022-02-20

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

放疗联合贝伐珠单抗治疗肺腺癌脑转移瘤伴脑水肿的临床效果

2022-08-15

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当

2022-08-30

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

建议收藏！贝伐珠单抗的4大常见不良反应，如何处理？

2023-01-08

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

关于贝伐珠单抗，你想知道的全在这里

2022-07-26

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗的中国人群标准剂量是多少？你真的知道吗？

2022-09-06

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性

2022-02-01

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究

2022-10-30

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗治疗非小细胞肺癌脑转移瘤放射治疗后难治性瘤周水肿疗效观察

2022-01-17

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗和安罗替尼在使用时如何选择？

2022-11-21

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效

2022-08-31

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性

2022-08-31

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）

2022-08-28

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后

2022-05-10

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗的加入让宫颈癌治疗不再“谈虎色变”（妇科肿瘤）

2022-08-02

科室
- - 订阅+
  - 更多科室
工具
服务